. Author manuscript; available in PMC: 2014 Feb 24.

Published in final edited form as: Cancer Chemother Pharmacol. 2008 Sep 16;63(6):1073–1082. doi: 10.1007/s00280-008-0826-3

Table 7.

Mean (±SD) CPT-11 and SN-38 Pharmacokinetic parameters following administration of irinotecan with mitomycin (no celecoxib) or with mitomycin ? celecoxib (celecoxib)

Parameter	No celecoxib (N = 37)	Celecoxib (N = 5)	P value^*
CPT-11
C_max (ng/mL)^a	1129 ± 228	1306 ± 159	0.1070
AUC 0–24 (ng h/mL)^*	8655 ± 3316	10626 ± 2799	0.1204
CL (L/h/m²)	13.0 ± 5.2	10.3 ± 3.0	0.2481
Vz (L/m²)	106 ± 42.2	84.5 ± 11.0	0.3446
t½ (h)	5.7 ± 0.7	5.9 ± 1.0	0.8173
SN-38
C_max (ng/mL)^a	27.3 ± 13.4	25.1 ± 5.7	0.9535
AUC 0–24 (ng h/mL)^*	274 ± 164	233 ± 92.7	0.8460
t½ (h)	11.1 ± 3.9	10.2 ± 2.3	0.8831
SN-38/CPT-11 AUC0–24 ratio	0.031 ± 0.012	0.030 ± 0.008	0.9381

Non-parametric Mann–Whitney test

Normalized to an irinotecan dose of 125 mg/m²